PatientsVille.com Logo


Kinson Medical Research Studies

Up-to-date List of Kinson Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Kinson Medical Research Studies

Rank Status Study
1 Recruiting Parkinsonism in Spinocerebellar Ataxia Type 6
Condition: Spinocerebellar Ataxia Type 6
Outcome Measures: The primary outcome would be the clinical feature of the Parkinsonism;   The primary outcome would also be the imaging feature of the Parkinsonism;   The secondary outcome would be the INAS score;   The secondary outcome would also be the SARA score
2 Recruiting MRI Study Looking at Resting Brain Activity in Healthy Adults and Individuals With Parkinsonism and Rapid Eye Movement Disorder.
Conditions: Movement Disorders (Incl Parkinsonism);   Tremor Familial Essential, 1;   REM Sleep Behavior Disorder
Outcome Measure: fMRI compared between cohorts
3 Unknown  Identification, Prevalence, and Lifespan of Rapid-Onset Dystonia-Parkinsonism
Conditions: Dystonia;   Parkinsonism
Outcome Measures: RDP Severity;   Presence of neuropsychiatric disease
4 Recruiting Measurement of Gait Using Opal APDM and Gait Mat in Parkinsonism
Condition: Parkinsonism
Interventions: Other: GAITRite;   Other: ADPM
Outcome Measures: gait and balance parameters;   gait and balance parameter
5 Unknown  Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS)
Conditions: Parkinson Disease;   Amyotrophic Lateral Sclerosis
Interventions: Drug: Xeomin;   Drug: placebo
Outcome Measure: Change in objectively measured salivary volume between baseline and one month post-injection in the Xeomin group as compared to placebo
6 Recruiting Study of Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS)
Condition: Sialorrhea
Interventions: Drug: Xeomin;   Drug: Placebo
Outcome Measure: Objectively Measured Salivary Volume
7 Recruiting Developing a Novel Imaging Biomarker in the Differential Diagnosis of Parkinson's Disease and Parkinsonism by 18F-DTBZ PET
Condition: Parkinson's Disease
Intervention: Drug: 18F-DTBZ
Outcome Measures: Analyzing the differences of monoaminergic degeneration between each group by comparing the SUVR of 18F- DTBZ measured by the VOIs methods in each brain region.;   Statistical parametrical mapping will be performed to compare the early-phase and delayed-phase imaging of 18F- DTBZ PET in each group.
8 Unknown  Botulinum Toxin for Treatment of Seborrhic Dermatitis in Parkinsonian Patients
Conditions: Parkinson Disease;   Parkinsonism;   Seborrheic Dermatitis
Intervention: Drug: Botulinum toxin
Outcome Measure: Clinical assesment of the rash Photometric test of sebum exertion
9 Unknown  Usefulness of α-synuclein as a Marker for Early Diagnosis of Parkinson's Disease in Skin Biopsy.
Conditions: Parkinson Disease;   Parkinsonian Disorders
Intervention: Procedure: Biopsy of skin
Outcome Measure: Fraction area of Alpha synuclein expression determined by immunohistochemistry in skin from patients with Parkinson disease and Parkinson Plus Syndromes, as a measure of selectively differentiate these two conditions.
10 Recruiting Development of a Novel 18F-DTBZ PET Imaging as a Biomarker to Monitor Neurodegeneration of PARK6 and PARK8 Parkinsonism
Condition: Parkinson's Disease
Intervention: Drug: 18F-DTBZ
Outcome Measures: To calculate the decline rate of striatal 18F-FP-(+)-DTBZ binding and to evaluate whether the degenerative rate differs between idiopathic PD patients and genetic-proving PARK6/PARK8 patients;   To analyze the correlation between decline rate of 18F-FP-(+)-DTBZ uptake and clinical severity, and access the feasibility of 18F-DTBZ PET imaging as an in vivo biomarker to monitor neurodegeneration in PD
11 Recruiting Clinical Trial to Evaluate Bone Marrow Stem Cell Therapy for PSP, a Rare Form of Parkinsonism
Condition: Progressive Supranuclear Palsy
Intervention: Biological: stem cell therapy
Outcome Measures: incidence of adverse events;   changes in brain images
12 Not yet recruiting Establishment of Clinical Basis for Hematopoietic Growth Factors Therapy in Brain Injury
Conditions: Neurological Diseases,;   Ischemic Stroke,;   Hemorrhagic Stroke,;   Cerebral Palsy,;   Atypical Parkinsonism
Interventions: Drug: Combination injection of EPO and G-CSF;   Drug: Injection of normal saline
Outcome Measures: Vital Sign;   Hematological Test;   Chest and Heart Evaluation;   Physical Assessment;   Occupational Assessment;   Psychological Assessment;   Verbal Assessment
13 Recruiting Identifying Biomarkers of Parkinson's Disease Using Magnetic Resonance Imaging (MRI)
Conditions: Parkinson's Disease (PD);   Parkinsonism;   Progressive Supranuclear Palsy (PSP);   Multiple System Atrophy (MSA)
Outcome Measures: Differential roles of fractional anisotropy (FA) and R2* in PD detection and progression;   Nigrostriatal diffusion tensor imaging (DTI) and R2* differentiate PD from parkinsonian syndromes;   Iron(Fe)-related proteins in body fluids as biomarkers of PD;   MRI and postmortem pathological correlation
14 Recruiting Repetitive Transcranial Magnetic Stimulation for Freezing of Gait
Condition: Parkinsonian Disorders
Interventions: Device: rTMS Motor cortex;   Device: rTMS Supplementary motor area
Outcome Measures: The number of steps;   The completion time during the SWS test;   Freezing episodes of gait trajectory;   Patient and Clinical Global Impression Scale
15 Recruiting A Trial of 18F-AV-133 Positron Emission Tomography (PET) Imaging to Differentiate Subjects With Parkinson's Disease (PD) From Other Movement Disorders
Conditions: Parkinson's Disease;   Primary Parkinsonism;   Lewy Body Parkinson's Disease
Intervention: Drug: 18F-AV-133
Outcome Measures: Sensitivity of visual read of AV-133 PET scan vs. standard of truth;   Specificity of visual read of AV-133 PET scan vs. standard of truth;   Inter-rater reliability of the visual read;   Intra-rater reliability of the visual read;   Probability of progressive motor skill impairment
16 Recruiting Evaluation of Safety and Tolerability of Fetal Mesencephalic Dopamine Neuronal Precursor Cells for Parkinson's Disease
Conditions: Idiopathic Parkinson Disease;   Primary Parkinsonism
Intervention: Drug: Mesencephalic Neuronal Precursor Cells
Outcome Measures: Presence or absence of cancer foramtion and infection;   Score of Unified Parkinson's Disease Rating Scale (UPDRS);   Detection of positron emission in Putamen using Positron emission tomograph(PET);   Dyskinesia scale scores(CAPSIT-PD);   Pronation-supination test, Hand/Arm movement between two points, finger dexterity, stand-walk-sit-test;   Score of activity of daily living (ADL) scale;   Score of Korean mini-mental examination (K-MMSE);   Motor fluctuation scale scores;   Satisfaction score with patient questionnaire;   Dopaminergic drug dose;   Tremor, postural instability, motor dysfunction, gait disturbance;   Assessing the extent of recovery with patient's diary
17 Recruiting Study of the Enteric Nervous System Using Colonic Biopsies in Parkinson Patients With LRRK2 Mutation
Condition: Parkinson's Disease
Intervention: Other: colonoscopy or rectosigmoidoscopy
Outcome Measures: Presence of alpha-synuclein aggregates in colonic biopsies using immunohistochemistry;   Analysis of intestinal permeability in biopsies using Ussing's chambers
18 Unknown  Clinical, Molecular and by Neuroimaging of LRRK2 Mutations
Condition: Parkinson's Disease
Outcome Measure:
19 Recruiting Positron Emission Tomography (PET) Imaging in People With Gaucher Mutations
Conditions: Glucocerebrosidase Mutations;   Gaucher Disease
Outcome Measure:
20 Recruiting Behavioural Addictions Occurring During a Dopaminergic Treatment Prescribe Under Parkinson's Disease: Study of the Psychopathological, Neurological and Pharmacokinetic Profiles
Conditions: Parkinson's Disease;   Secondary Behavioural Addiction
Intervention: Other: questionnaires
Outcome Measures: Psychopathological axis : score of sensation seeking (S Score) of the impulsivity questionnaire "UPPS";   Pharmacological axis : Area under the curve of the pramipexole concentration;   Neurological axis : Unified Parkinson's Disease Rating Scale (UPDRS) III score;   Treatments except the anti-Parkinsonism ones;   drug misuse;   addiction and punding antecedents;   ADHD antecedents;   impulsivity profile;   Age of onset of the Parkinson's disease;   stage and form of the Parkinson's disease;   time course of Parkinson's disease;   family history of Parkinson's disease;   anti-Parkinsonism treatments;   Residual plasmatic concentration of the pramipexole;   median pharmacokinetic parameters of pramipexole;   study of the hepatic and renal functions;   Physiopathological covariates

These studies may lead to new treatments and are adding insight into Kinson etiology and treatment.

A major focus of Kinson research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Kinson